Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 3/2011

01.06.2011

Does Blood Pressure Variability Modulate Cardiovascular Risk?

verfasst von: Peter M. Rothwell

Erschienen in: Current Hypertension Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Exactly how hypertension causes end organ damage and vascular events is poorly understood. Yet the concept that underlying “usual” blood pressure (BP) accounts for all BP-related risk of vascular events and for the benefits of BP-lowering drugs has come to underpin clinical guidelines on the diagnosis and treatment of hypertension. This article reviews evidence that variability in BP also predicts risk of stroke and other vascular events independently of mean BP and evidence that drug-class effects on variability in BP explain differences in the effectiveness of BP-lowering drugs in preventing stroke.
Literatur
1.
Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.PubMedCrossRef
2.
Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.PubMedCrossRef
3.
Beckett LA, Rosner B, Roche AF, Guo S. Serial changes in blood pressure from adolescence into adulthood. Am J Epidemiol. 1992;135:1166–77.PubMed
4.
Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–15.PubMedCrossRef
5.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.​1136/​bmj.​b1665.PubMedCrossRef
6.
Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.PubMedCrossRef
7.
Rothwell PM, Howard SC, Dolan E. et al; on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.PubMedCrossRef
8.
Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–15.PubMedCrossRef
9.
Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938–48.PubMedCrossRef
10.
Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of BP measured casually and by portable recorders and severity of complications in essential hypertension. Circulation. 1966;34:279–98.PubMed
11.
Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour BP variability. J Hypertens. 1993;11:1133–37.PubMedCrossRef
12.
Pessina AC, Palatini P, Sperti G, et al. Cordone. Evaluation of hypertension and related target organ damage by average day-time BP. Clin Exp Hypertens. 1985;A7:267–78.CrossRef
13.
Veerman DP, de Blok K, Delemarre BJ, van Montfrans GA. Office, nurse, basal and ambulatory BP as predictors of hypertensive target organ damage in male and female patients. J Hum Hypertens. 1996;10:9–15.PubMed
14.
Veerman DP, de Blok K, van Montfrans A. Relationship of steady state and ambulatory BP variability to left ventricular mass and urinary albumin excretion in essential hypertension. Am J Hypertens. 1996;9:455–60.PubMedCrossRef
15.
Mancia G, Parati G, Hennig M, et al. ELSA Investigators. Relation between BP variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19:1981–89.PubMedCrossRef
16.
Sega R, Corrao G, Bombelli M, et al. BP variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710–14.PubMedCrossRef
17.
Tatasciore A, Renda G, Zimarino M, et al. Awake systolic BP variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007;50:325–32.PubMedCrossRef
18.
Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of BP variability to carotid atherosclerosis and carotid artery and left ventricular hypertrophy. Atheroscler Thromb Vasc Biol. 2001;21:1507–11.CrossRef
19.
Tohgi H, Chiba K, Kimura M. Twenty-four-hour variation of BP in vascular dementia of the Binswanger type. Stroke. 1991;22:603–8.PubMed
20.
Mart-Fabregas J, Valencia C, Pujol J, et al. BP variability and leukoaraiosis amount in cerebral small-vessel disease. Acta Neurol Scand. 2001;104:358–63.CrossRef
21.
Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension. 1990;16:692–9.PubMed
22.
Goldstein IB, Bartzokis G, Hance DB, Shapiro D. Relationship between BP and subcortical lesions in healthy elderly people. Stroke. 1998;29:765–72.PubMed
23.
Skoog I. A review on BP and ischaemic white matter lesions. Dement Geriatr Cogn Disord 1989(suppl 1): 13–19.
24.
Puisieux F, Monaca P, Deplanque D, et al. Relationship between leuko-araiosis and BP variability in the elderly. Eur Neurol. 2001;46:115–20.PubMedCrossRef
25.
Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory BP and brain atrophy in the healthy elderly. Neurology. 2002;59:713–19.PubMed
26.
Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory BP and the brain: a 5-year follow-up. Neurology. 2005;64:1846–52.PubMedCrossRef
27.
Kanemaru A, Kanemaru K, Kuwajima I. The effects of short-term BP variability and nighttime BP levels on cognitive function. Hypertens Res. 2001;24:19–24.PubMedCrossRef
28.
Kawamoto A, Shimada K, Matsubayashi K, et al. Factors associated with silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic elderly hypertensive patients. Clin Exp Pharmacol Physiol. 1991;18:605–10.PubMedCrossRef
29.
Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens. 2002;20:519–24.PubMedCrossRef
30.
Pickering TG, James GD. Ambulatory BP and prognosis. J Hypertens. 1994;12 suppl 8:S29–33.
31.
James GD, Pickering TG, Laragh JH. Ambulatory BP variation is related to plasma renin activity in borderline hypertensive men. Am J Hypertens. 1991;4:525–28.PubMed
32.
Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of BP and heart rate variabilities: the Ohasama study. Hypertension. 2000;36:901–6.PubMed
33.
Pringle E, Phillips C, Thijs L, et al. Syst-Eur investigators. Systolic BP variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21:2251–7.PubMedCrossRef
34.
Jokiniitty JM, Majahalme SK, Kahonen MA, Tuomisto MT, Turjanmaa VM. Prediction of blood pressure level and need for antihypertensive medication: 10 years of follow-up. J Hypertens. 2001;19:1193–201.PubMedCrossRef
35.
Sander D, Kukla C, Klingelhoffer J, Winbeck K, Conrad B. Relationship between circadian BP patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536–41.PubMed
36.
Eto M, Toba K, Akishita M, et al. Impact of BP variability on cardiovascular events in elderly patients with hypertension. Hypertens Res. 2005;28:1–7.PubMedCrossRef
37.
Verdecchia P et al. Prognostic significance of BP variability in essential hypertension: univariate and multivariate assessment. BP Monitoring. 1996;1:3–11.
38.
Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368–74.PubMedCrossRef
39.
Hansen TW, Thijs L, Li Y, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55:1049–57.PubMedCrossRef
40.
Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Enhanced blood pressure variability in a high cardiovascular risk group of African Americans: FIT4Life Study. J Am Soc Hypertens. 2010;4:187–95.PubMedCrossRef
41.
Ko Y, Park JH, Yang MH, et al. The significance of blood pressure variability for the development of hemorrhagic transformation in acute ischemic stroke. Stroke. 2010;41:2512–8.PubMedCrossRef
42.
Armitage P, Fox W, Rose GA, Tinker CM. The variability of measurement of casual BP: ii Survey experience. Clin Sci. 1966;30:337–44.PubMed
43.
Rosner B, Polk BF. The implications of BP variability for clinical and screening purposes. J Chron Dis. 1979;32:451–61.PubMedCrossRef
44.
Hebel JR, Apostolides AY, Dischinger P, Entwistle G, Su S. Within-person variability in diastolic BP for a cohort of normotensives. J Chronic Dis. 1980;33:745–50.PubMedCrossRef
45.
Shepard DS. Reliability of BP measurements: implications for designing and evaluating programs to control hypertension. J Chronic Dis. 1981;34:191–209.PubMedCrossRef
46.
Rosner B, Polk BF. Predictive values of routine BP measurements in screening for hypertension. Am J Epidemiol. 1983;117:429–42.PubMed
47.
Rosner B, Polk BF. The implications of BP variability for clinical and screening purposes. J Chron Dis. 1979;32:451–61.PubMedCrossRef
48.
Cook NR, Rosner BA. Screening rules for determining BP status in clinical trials. Application to the trials of hypertension prevention. Am J Epidemiol. 1993;137:1341–52.PubMed
49.
Markovic N, Olomu IN, Bunker CH, et al. Adequacy of a single visit for classification of hypertensive status in a Nigerian civil servant population. Int J Epidemiol. 1994;23:723–9.PubMedCrossRef
50.
Klungel OH, de Boer A, Paes AHP, et al. Estimating the prevalence of hypertension corrected for the effect of within-person variability in BP. J Clin Epidemiol. 2000;53:1158–63.PubMedCrossRef
51.
Klungel OH, de Boer A, Paes AH, et al. Influence of correction for within-person variability in BP on the prevalence, awareness, treatment, and control of hypertension. Am J Hypertens. 2000;13:88–91.PubMedCrossRef
52.
Wittes J, Lakatos E, Black D, et al. Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. Control Clin Trials. 1999;20:121–32.PubMedCrossRef
53.
Alli C, Mariotti G, Avanzini F, et al. Long-term prognostic impact of repeated measurements over 1 year of pulse pressure and systolic BP in the elderly. J Hum Hypertens. 2005;19:355–63.PubMedCrossRef
54.
Imai Y, Ohkubo T, Tsuji I, et al. Relationships among BPs obtained using different measurement methods in the general population of Ohasama, Japan. Hypertens Res. 1999;22:261–72.PubMedCrossRef
55.
Mancia G, Parati G, Bilo G, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory BP: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25:1087–94.PubMedCrossRef
56.
Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning BP in older patients with isolated systolic hypertension. J Hypertens. 2008;26:1328–35.PubMedCrossRef
57.
Brueren MM, van Limpt P, Schouten HJ, et al. Is a series of BP measurements by the general practitioner or the patient a reliable alternative to ambulatory BP measurement? A study in general practice with reference to short-term and long-term between-visit variability. Am J Hypertens. 1997;10:879–85.PubMedCrossRef
58.
Hata Y, Kimura Y, Muratani H, et al. Office BP variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res. 2000;23:553–60.PubMedCrossRef
59.
Hata Y, Muratani H, Kimura Y, et al. Office BP variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens. 2002;16:141–6.PubMedCrossRef
60.
Tozawa M, Iseki K, Yoshi S, Fukiyama K. BP variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant. 1999;14:1976–81.PubMedCrossRef
61.
Havlik RJ, Foley DJ, Sayer B, et al. Variability in midlife systolic BP is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke. 2002;33:26–30.PubMedCrossRef
62.
Wingfield D, Grodzicki T, Palmer AJ, Wells F, Bulpitt CJ, on behalf of the General Practice Hypertension Study Group. Transiently elevated diastolic BP is associated with a gender-dependent effect on cardiovascular risk. J Hum Hypertens. 2005;19:347–54.PubMedCrossRef
63.
Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045–50.PubMedCrossRef
64.
Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160–6.PubMedCrossRef
65.
Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care. 2010;33:2442–7.PubMedCrossRef
66.
Geeganage C, Tracy M, England T, et al. TAIST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke. 2011;42:491–3.PubMedCrossRef
67.
Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning BP in older patients with isolated systolic hypertension. J Hypertens. 2008;26:1328–35.PubMedCrossRef
68.
Kario K, Shimada K, Pickering TG. Clinical implication of morning BP surge in hypertension. J Cardiovasc Pharmacol. 2003;42 Suppl 1:S87–91.PubMedCrossRef
69.
Koton S, Tanne D, Bornstein NM, Green MS. Triggering risk factors for ischemic stroke: a case-crossover study. Neurology. 2004;63:2006–10.PubMed
70.
Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet. 2007;370:1089–100.PubMedCrossRef
71.
Kazuomi K. Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk. Circ J. 2009;73:1002–7.CrossRef
72.
Fessel J, Robertson D. Orthostatic hypertension: when pressor reflexes overcompensate. Nat Clin Pract Nephrol. 2006;2:424–31.PubMedCrossRef
73.
Pavek K, Taube A. Personality characteristics influencing determinacy of day and night blood pressure and heart rate. Blood Press. 2009;18:30–5.PubMedCrossRef
74.
Brondolo E, Grantham KI, Karlin W, et al. Trait hostility and ambulatory blood pressure among traffic enforcement agents: the effects of stressful social interactions. J Occup Health Psychol. 2009;14:110–21.PubMedCrossRef
75.
Federowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Prevention Project). Eur Heart J. 2010;31:85–91.CrossRef
76.
Hossain M, Ooi WL, Lipsitz LA. Intra-individual postural blood pressure variability and stroke in elderly nursing home residents. J Clin Epidemiol. 2001;54:488–94.PubMedCrossRef
77.
Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British Women's Heart and Health Study. Age Ageing. 2010;39:51–6.PubMedCrossRef
78.
Verdecchia P, O'Brien E, Pickering T, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Am J Hypertens. 2003;16:87–91.PubMedCrossRef
79.
Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846–53.PubMedCrossRef
80.
Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32.PubMedCrossRef
81.
Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. Hypertens Res. 2007;30:479–88.PubMedCrossRef
82.
Heuschmann PU, Grieve AP, Toschke AM, Rudd AG, Wolfe CD. Ethnic group disparities in 10-year trends in stroke incidence and vascular risk factors: the South London Stroke Register (SLSR). Stroke. 2008;39:2204–10.PubMedCrossRef
83.
Duprez DA, Jacobs Jr DR, Lutsey PL, et al. Race/ethnic and sex differences in large and small artery elasticity–results of the multi-ethnic study of atherosclerosis (MESA). Ethn Dis. 2009;19:243–50.PubMed
84.
Tozawa M, Iseki K, Yoshi S, Fukiyama K. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant. 1999;14:1976–81.PubMedCrossRef
85.
Fischer U, Bull L, Silver LE, Mehta Z, Rothwell PM. Acute phase blood pressure after TIA and stroke in relation to pre-morbid levels: a population based study. Cerebrovasc Dis. 2009;27 suppl 6:60 (Abstract).
86.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRef
87.
MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–12.CrossRef
88.
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed). 1985;291:97–104.CrossRef
89.
Angeli F, Verdicchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817–22.PubMed
90.
Webb AJS, Rothwell PM. Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs. Stroke. 2010;41:2091–3.PubMedCrossRef
91.
Web AJS, Fischer U, Rothwell PM. Detrimental effects of non-selective beta-blockers on blood pressure variability and risk of stroke: A systematic review. Neurology 2011 (in press).
92.
Miao CY, Xie HH, Zhan LS, Su DF. BP variability is more important than BP level in determination of end-organ damage in rats. J Hypertens. 2006;24:1125–35.PubMedCrossRef
93.
Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol. 2001;38:427–37.PubMedCrossRef
94.
Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol. 2006;21:486–91.PubMedCrossRef
95.
Tatasciore A, Zimarino M, Renda G, et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res. 2008;31:2137–46.PubMedCrossRef
96.
Desjardins F, Sekkali B, Verreth W, et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J. 2008;29:128–37.PubMedCrossRef
97.
Sorond FA, Khavari R, Serrador JM, Lipsitz LA. Regional cerebral autoregulation during orthostatic stress: age-related differences. J Gerontol A Biol Sci Med Sci. 2005;60:1484–7.PubMed
98.
Zhang R, Witkowski S, Fu Q, Claassen JA, Levine BD. Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension. 2007;49:1149–55.PubMedCrossRef
99.
Rothwell PM, Howard SC, Spence D. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34:2583–90.PubMedCrossRef
100.
Lammie GA, Lindley R, Keir S, Wiggam MI. Stress-related primary intracerebral hemorrhage: autopsy clues to underlying mechanism. Stroke. 2000;31:1426–8.PubMed
101.
Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer's disease. Ann NY Acad Sci. 1997;826:103–16.PubMedCrossRef
102.
Meyer JS, Waltz AG, Gotoh F. Pathogenesis of cerebral vasospasm in hypertensive encephalopathy. I. Effects of acute increases in intraluminal blood pressure on pial blood flow. Neurology. 1960;10:735–44.
103.
Thom S, Stettler C, Stanton A, et al. Differential effects of antihypertensive treatment on the retinal microcirculation: an Anglo-Scandinavian Cardiac Outcomes Trial substudy. Hypertension. 2009;54:405–8.PubMedCrossRef
Metadaten
Titel
Does Blood Pressure Variability Modulate Cardiovascular Risk?
verfasst von
Peter M. Rothwell
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 3/2011
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0201-3

Weitere Artikel der Ausgabe 3/2011

Current Hypertension Reports 3/2011 Zur Ausgabe

ReviewPaper

Sympathetic Neural Mechanisms in Human Blood Pressure Regulation

ReviewPaper

Mineralocorticoid Actions in the Brain and Hypertension

ReviewPaper

New Approaches to Quantifying Sympathetic Nerve Activity

ReviewPaper

Vitamin D Therapy and Cardiovascular Health

ReviewPaper

Vascular Mechanisms in the Pathogenesis of Stroke

ReviewPaper

Stress and Its Role in Sympathetic Nervous System Activation in Hypertension and the Metabolic Syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise